AUPH

AI Memo

Aurinia

As of 2026-10-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

2026 LUPKYNIS sales versus guidance • 2026-12-31

Base target: $18 / p=50% prob

Biggest risk

2026 revenue guidance was reiterated, not raised. LUPKYNIS remains the principal product-sales driver; other generic-patent actions continue, while PRESERVE and aritinercept have no dated efficacy readouts in the supplied evidence. Zacks reported a Q2 EPS beat versus its consensus estimate, but a slight revenue miss and unfavorable pre-print estimate revisions; post-print revisions are unavailable.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Q2 revenue grew 19% year over year to $83.2 million, net income rose to $37.4 million, and operating cash flow reached $52.5 million. Continued LUPKYNIS growth, cash generation and the Teva settlement support a cautiously positive view. [#SEC-8K-2026-08-06] [#8-K-2026-08-19]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

$18

p=50%

Bull target

$21

p=30%

Bear target

$12

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PRESERVE combination-study progress
Aritinercept clinical development
Remaining generic-patent litigation

BearKey bullets

Commercial concentration in LUPKYNIS makes sales and reimbursement execution central to 2026 guidance.
[#SEC-8K-2026-08-06]
Generic-patent litigation continues against applicants other than Teva; the Teva settlement includes earlier-launch contingencies.

WatchKey bullets

2026 LUPKYNIS sales versus guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $18 (p=50%)

Target spread vs base: +17% / -33%

Scenario probabilities

Bull Target: $21 (p=30%)Base Target: $18 (p=50%)Bear Target: $12 (p=20%)

Commentary

Primary-source operating results and the Teva settlement support the packet's positive directional prior, but a reliable post-release price reaction and post-print analyst revisions were not supplied. Recent headline coverage is thin. Zero-valued sentiment fields denote unavailable measurements, not neutral or zero actual readings.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PRESERVE combination-study progress
Aritinercept clinical development
Remaining generic-patent litigation

Scenarios

Bull Target (Scenario probability)

$21 / p=30% prob

Base Target (Scenario probability)

$18 / p=50% prob

Bear Target (Scenario probability)

$12 / p=20% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
2026 LUPKYNIS sales versus guidance
Q2 LUPKYNIS net product sales rose 19% year over year to $79.4 million. Aurinia reiterated 2026 net product sales guidance of $305 million–$315 million; delivery against that range is the clearest commercial test. [#SEC-8K-2026-08-06]
Prob 65.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PRESERVE combination-study progress
2027-10-18
Aurinia initiated the Phase 4 PRESERVE study of LUPKYNIS with selected biologics in lupus nephritis. Enrollment and eventual six-month renal-response data could inform combination use, but no readout date was supplied. [#SEC-8K-2026-08-06]
Prob 45% • Move 8% • Priced-in 20%
Aritinercept clinical development
2027-10-18
Aurinia said it had initiated clinical development of aritinercept in four potential autoimmune indications. Program-specific progress may broaden the pipeline thesis, but the supplied release gives no dated efficacy readout. [#PR-EARNINGS-2026-08-06]
Prob 40% • Move 9% • Priced-in 25%
Remaining generic-patent litigation
2027-10-18
The Teva settlement bars its proposed U.S. generic voclosporin launch before December 7, 2036, subject to earlier contingencies and FDA approval. Aurinia disclosed continuing actions against other generic applicants, so exclusivity risk remains unresolved. [#8-K-2026-08-19]
Prob 55% • Move 8% • Priced-in 65%

Risks

Commercial concentration in LUPKYNIS makes sales and reimbursement execution central to 2026 guidance. [#SEC-8K-2026-08-06]
Generic-patent litigation continues against applicants other than Teva; the Teva settlement includes earlier-launch contingencies. [#8-K-2026-08-19]
PRESERVE combination benefit and aritinercept efficacy remain unproven; no dated readouts were supplied. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-08-06]
Repurchases use capital that could otherwise support pipeline development; the company reported $74.9 million of first-half share repurchases. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
CLDX	Similar market capitalization, but its development-stage portfolio is not a direct LUPKYNIS commercial or lupus-nephritis comparison.
HRMY	Comparable market capitalization and specialty-drug commercialization, but different indications and pipeline risks make it a loose valuation peer.
IRON	Similar market capitalization, but clinical-stage economics differ materially from Aurinia's profitable LUPKYNIS franchise.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

CLDX

Similar market capitalization, but its development-stage portfolio is not a direct LUPKYNIS commercial or lupus-nephritis comparison.

HRMY

Comparable market capitalization and specialty-drug commercialization, but different indications and pipeline risks make it a loose valuation peer.

IRON

Similar market capitalization, but clinical-stage economics differ materially from Aurinia's profitable LUPKYNIS franchise.